Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Ian M CatlettMiroslawa NowakSudeep KunduNaiyu ZhengAng LiuBing HeIhab G GirgisDennis M GraselaPublished in: British journal of clinical pharmacology (2020)
Rapid and high occupancy of BTK and the lack of notable safety findings support further clinical development of branebrutinib.